TY - JOUR
T1 - Hydrogen sulfide inhibits human platelet aggregation
AU - Zagli, Giovanni
AU - Patacchini, Riccardo
AU - Trevisani, Marcello
AU - Abbate, Rosanna
AU - Cinotti, Sandro
AU - Gensini, Gian Franco
AU - Masotti, Giulio
AU - Geppetti, Pierangelo
PY - 2007/3/15
Y1 - 2007/3/15
N2 - Gaseous mediators such as nitric oxide (NO) play a major regulatory role in the cardiovascular system homeostasis, including platelet aggregation. Here, we investigated whether hydrogen sulfide (H2S), a newly recognized endogenous mediator, can affects aggregation of human platelets, using sodium hydrogen sulfide (NaHS) as H2S-donor. NaHS inhibited platelet aggregation induced by ADP, collagen, epinephrine, arachidonic acid, thromboxane mimetic, U46619, and thrombin. H2S effect was not dependent by cAMP/cGMP generation, NO production or potassium-channels opening. NaHS concentrations (up to 10 mM) did not exert toxic effects on platelet viability. The possible protective role of endogenous H2S in cardiovascular system is discussed.
AB - Gaseous mediators such as nitric oxide (NO) play a major regulatory role in the cardiovascular system homeostasis, including platelet aggregation. Here, we investigated whether hydrogen sulfide (H2S), a newly recognized endogenous mediator, can affects aggregation of human platelets, using sodium hydrogen sulfide (NaHS) as H2S-donor. NaHS inhibited platelet aggregation induced by ADP, collagen, epinephrine, arachidonic acid, thromboxane mimetic, U46619, and thrombin. H2S effect was not dependent by cAMP/cGMP generation, NO production or potassium-channels opening. NaHS concentrations (up to 10 mM) did not exert toxic effects on platelet viability. The possible protective role of endogenous H2S in cardiovascular system is discussed.
KW - Cardiovascular risk factor
KW - HS
KW - Hydrogen sulfide
KW - Platelet inhibition
KW - Thromboembolic disease
UR - http://www.scopus.com/inward/record.url?scp=33847078111&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33847078111&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2006.12.011
DO - 10.1016/j.ejphar.2006.12.011
M3 - Article
C2 - 17291489
AN - SCOPUS:33847078111
VL - 559
SP - 65
EP - 68
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
SN - 0014-2999
IS - 1
ER -